Jiménez-Aguilar R, Rodriguez-Godoy ME, Jiménez-Juarez RN, Cano-Salas MC

Language: Spanish
References: 15
Page: 207-210
PDF size: 624.83 Kb.

ABSTRACT

Introduction: The Respiratory Syncytial Virus (RSV) is the most important viral pathogen in children under 2 years of age, which warrants hospitalization for a low respiratory infection. 0.5% of children under 5 with RSV infection require hospitalization. The aim of this case is to reaffirm the importance of this virus as a cause of severe disease and to emphasize the importance of adequate diagnosis and management to improve prognosis.
Clinical case: Child of 1 year 3 months old, without risk factors for severe infection by respiratory viruses. A 3- day course of respiratory failure, requiring mechanical ventilation with a pulmonary protection strategy due to the development of intra-pulmonary ARDS, was considered a mixed infection and received antibacterial treatment. During his hospitalization, RSV infection was documented. He was graduated without pulmonary sequelae.
Conclusions: Respiratory syncytial virus is the respiratory virus that causes a greater burden of disease, even above influenza. Unfortunately for children without risk factors for severe infection there are no options for prevention or treatment, so in subjects with severe disease the only option is the management of support in specialized units and the timely detection of bacterial overinfection. The development of a vaccine is necessary.

REFERENCES

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to RSV in young children. Lancet. 2010;375:1545-55.

2. Instituto Mexicano del Seguro Social, Dirección General de Epidemiología. Medicina Basada en la Evidencia y Guías de Práctica Clínica. México, D.F.: IMSS; 2014. Disponible en: www.imss.gob.mx/sites/all/statics/profesionalesSalud/gpc/ MBEyGPC.pdf

3. Collins P, Crowe J. Paramyxoviridae: Respiratory Syncytial Virus and Metapneumovirus. En: Knipe D., Howley P. Fields Virology. 5th Edition. Volume II, Section II. 2007.

4. Escobar B, Luchsinger V, Palomino M, Avendaño L. Gravedad clínica de la infección respiratoria aguda baja primaria por Metapneumovirus humano y virus respiratorio sincicial. Revista Pediátrica. 2006;2:1-4.

5. Mullins JA, Lamonte AC, Bresee JS. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J. 2003;22:857-862.

6. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917-28.

7. Ogra PL. Respiratory syncytial virus: The virus, the disease and the immune response. Paediatric Respiratory Reviews. 2004;5(Suppl A):S119-S126.

8. McCarthy CA, Hall CB. Respiratory Syncytial Virus: Concerns and Control. Pediatrics in Review. 2003;24:301- 309.

9. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The Burden of Respiratory Syncytial Virus Infection in Young Children. N Engl J Med. 2009;360:588-98.

10. Rodríguez DA, Rodríguez-Martínez CE, Cárdenas AC, Quilaguy IL, Mayorga LY, Falla LM, Nino G. Predictors of severity and mortality in children hospitalized with 2 respiratory syncytial virus infection in a tropical region. Pediatric Pulmonology. 2014;49:269-276.

11. Vizcarra-Ugalde S, Monjarás-Ávila C, Bernal-Silva S, Garrocho-Rangel ME, Ochoa-Pérez UR, Noyola DE. Intensive Care Unit Admission and Death Rates of Infants Admitted With Respiratory Syncytial Virus Lower Respiratory Tract Infection in Mexico. Pediatr Infect Dis J. 2016;35:1199-1203.

12. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835-45.

13. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620-38

14. Salinas-Escudero G, Martínez-Valverde S, Reyes-López A, Garduño-Espinosa J, Muñoz-Hernández O, Granados- García V, Rely K. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico. Salud Pública Mex. 2012;54:47-59.

15. Gamiño-Arroyo AE, Moreno-Espinosa S, Llamosas- Gallardo B, Ortiz-Hernández AA, Guerrero ML, Galindo- Fraga A, et al. Mexico Emerging Infectious Diseases Clinical Research Network (La Red). Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. Influenza Other Respir Viruses. 2017;11:48-56.